InflaRx Valuation Multiples

InflaRx Overview

About InflaRx

InflaRx NV is a clinical-stage biopharmaceutical company focused on applying proprietary anti-C5a/C5aR technology to discover and develop first-in-class, potent, and specific inhibitors of the complement activation factor known as C5a and its receptor known as C5aR. C5a is an inflammatory mediator involved in the progression of a wide variety of autoimmune and other inflammatory diseases. Its product candidate, vilobelimab, is a novel intravenously delivered first-in-class anti-C5a monoclonal antibody that selectively binds to free C5a and has demonstrated disease-modifying clinical activity and tolerability in multiple clinical settings.

Founded

2007

HQ

Employees

74

Website

inflarx.de

Sectors

BiopharmaceuticalsBioTech

Financials (LTM)

Revenue: $31K

EBITDA: ($57M)

EV

$11M

Valuation Multiples

Multiples.vc

Start free trial

InflaRx Financials

InflaRx reported last 12-month revenue of $31K and negative EBITDA of ($57M).

In the same LTM period, InflaRx generated ($5M) in gross profit, ($57M) in EBITDA losses, and had net loss of ($50M).

InflaRx P&L

In the most recent fiscal year, InflaRx reported revenue of $205K and EBITDA of ($52M).

InflaRx expects next 12-month revenue of XXX and NTM EBITDA of XXX

InflaRx Stock Performance

InflaRx has current market cap of $62M, and enterprise value of $11M.

InflaRx's stock price is $0.92.

InflaRx Valuation Multiples

InflaRx trades at 360.3x EV/Revenue multiple, and (0.2x) EV/EBITDA.

InflaRx Financial Valuation Multiples

As of March 21, 2026, InflaRx has market cap of $62M and EV of $11M.

Equity research analysts estimate InflaRx's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX

InflaRx has a P/E ratio of (1.2x).

InflaRx Margins & Growth Rates

InflaRx's revenue in the last 12 month declined by (17%).

InflaRx's revenue per employee in the last FY averaged $0.0M.

InflaRx's rule of 40 is (180347%) (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).

InflaRx's rule of X is (180371%) (created by Bessemer, rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).

InflaRx Public Comps

See public comps and valuation multiples for other Biopharmaceuticals comps.

InflaRx M&A Activity

InflaRx acquired XXX companies to date.

Last acquisition by InflaRx was on XXXXXXXX, XXXXX. InflaRx acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).

InflaRx Investment Activity

InflaRx invested in XXX companies to date.

InflaRx made its latest investment on XXXXXXXX, XXXXX. InflaRx invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).